{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:26:02Z","timestamp":1783445162728,"version":"3.54.6"},"reference-count":118,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020608","name":"University of Technology and Applied Sciences - Muscat","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biotechnology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jbiotec.2026.06.012","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:19:16Z","timestamp":1781626756000},"page":"246-264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["CRISPR Cas9 revolutionizing genetic engineering and therapeutic applications"],"prefix":"10.1016","volume":"417","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5228-0145","authenticated-orcid":false,"given":"Sivakumar","family":"Durairaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Durairaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7156-1057","authenticated-orcid":false,"given":"Sundar","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Raju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jbiotec.2026.06.012_bib1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.21775\/cimb.028.047","article-title":"A review of CRISPR-based genome editing: survival, evolution and challenges","volume":"28","author":"Ahmad","year":"2018","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.jbiotec.2026.06.012_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1675682","article-title":"Precision bacterial immunotherapy: an integrated mechanistic taxonomy and translational roadmap against antimicrobial resistance","volume":"16","author":"Al-Azzani","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jbiotec.2026.06.012_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.639475","article-title":"Treatment of cystic fibrosis: from gene-to cell-based therapies","volume":"12","author":"Allan","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jbiotec.2026.06.012_bib4","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/978-1-59745-458-2_42","article-title":"Gene therapy in the treatment of human cancer","author":"Annan","year":"2017","journal-title":"Mol. Basis Human. Cancer"},{"issue":"7785","key":"10.1016\/j.jbiotec.2026.06.012_bib5","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jbiotec.2026.06.012_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113324","article-title":"Gene therapy clinical trials, where do we go? An overview","volume":"153","author":"Arabi","year":"2022","journal-title":"Biomed. & Pharmacother."},{"issue":"2","key":"10.1016\/j.jbiotec.2026.06.012_bib7","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3906\/biy-1912-52","article-title":"Bioethical issues in genome editing by CRISPR-Cas9 technology","volume":"44","author":"Ayano\u011flu","year":"2020","journal-title":"Turk. J. Biol."},{"key":"10.1016\/j.jbiotec.2026.06.012_bib8","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00294-019-01040-3","article-title":"A glance at genome editing with CRISPR\u2013Cas9 technology","volume":"66","author":"Barman","year":"2020","journal-title":"Curr. Genet."},{"key":"10.1016\/j.jbiotec.2026.06.012_bib9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11569-016-0259-0","article-title":"CRISPR\/Cas9 genome editing\u2013new and old ethical issues arising from a revolutionary technology","volume":"10","author":"Baumann","year":"2016","journal-title":"NanoEthics"},{"issue":"2","key":"10.1016\/j.jbiotec.2026.06.012_bib10","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1021\/acsomega.2c05583","article-title":"Insights into the mechanism of CRISPR\/Cas9-based genome editing from molecular dynamics simulations","volume":"8","author":"Bhattacharya","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.jbiotec.2026.06.012_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fgeed.2020.613252","article-title":"Gene editing and genotoxicity: targeting the off-targets","volume":"2","author":"Blattner","year":"2020","journal-title":"Front. Genome Ed."},{"issue":"1","key":"10.1016\/j.jbiotec.2026.06.012_bib12","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jmb.2018.05.044","article-title":"CRISPR ethics: moral considerations for applications of a powerful tool","volume":"431","author":"Brokowski","year":"2019","journal-title":"J. Mol. Biol."},{"issue":"3","key":"10.1016\/j.jbiotec.2026.06.012_bib13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/hgtb.2018.187","article-title":"Development of CRISPR-mediated systems in the study of Duchenne muscular dystrophy","volume":"30","author":"Cai","year":"2019","journal-title":"Human. gene Ther. Methods"},{"issue":"22","key":"10.1016\/j.jbiotec.2026.06.012_bib14","doi-asserted-by":"crossref","first-page":"13596","DOI":"10.1021\/acscatal.0c03566","article-title":"Catalytic mechanism of non-target DNA cleavage in CRISPR-Cas9 revealed by ab initio molecular dynamics","volume":"10","author":"Casalino","year":"2020","journal-title":"ACS Catal."},{"issue":"1","key":"10.1016\/j.jbiotec.2026.06.012_bib15","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1146\/annurev-genom-083117-021702","article-title":"Genetic disorders of the extracellular matrix: from cell and gene therapy to future applications in regenerative medicine","volume":"23","author":"Chakravarti","year":"2022","journal-title":"Annu. Rev. Genom. Human. Genet."},{"key":"10.1016\/j.jbiotec.2026.06.012_bib16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/bs.pmbts.2018.05.001","article-title":"Different methods of delivering CRISPR\/Cas9 into cells","volume":"159","author":"Chandrasekaran","year":"2018","journal-title":"Progress. Mol. Biol. Transl. Sci."},{"issue":"6","key":"10.1016\/j.jbiotec.2026.06.012_bib17","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1172\/JCI136873","article-title":"Correction of muscular dystrophies by CRISPR gene editing","volume":"130","author":"Chemello","year":"2020","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.jbiotec.2026.06.012_bib18","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.canlet.2019.01.017","article-title":"CRISPR-Cas9 for cancer therapy: Opportunities and challenges","volume":"447","author":"Chen","year":"2019","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.jbiotec.2026.06.012_bib19","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.drudis.2021.11.018","article-title":"Modulating CRISPR\/Cas9 genome-editing activity by small molecules","volume":"27","author":"Chen","year":"2022","journal-title":"Drug. Discov. Today"},{"issue":"1","key":"10.1016\/j.jbiotec.2026.06.012_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41434-020-00197-8","article-title":"Gene therapy and gene correction: targets, progress, and challenges for treating human diseases","volume":"29","author":"Cring","year":"2022","journal-title":"Gene Ther."},{"issue":"7","key":"10.1016\/j.jbiotec.2026.06.012_bib21","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jcyt.2018.04.003","article-title":"Gene therapy for sickle cell disease: An update","volume":"20","author":"Demirci","year":"2018","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jbiotec.2026.06.012_bib22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/5584_2018_331","article-title":"CRISPR\/Cas9 for sickle cell disease: applications, future possibilities, and challenges","author":"Demirci","year":"2019","journal-title":"Cell Biology Translational Medicine Volume 5 Stem Cells Translational Science Therapy"},{"issue":"6213","key":"10.1016\/j.jbiotec.2026.06.012_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/science.1258096","article-title":"The new frontier of genome engineering with CRISPR-Cas9","volume":"346","author":"Doudna","year":"2014","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.jbiotec.2026.06.012_bib24","doi-asserted-by":"crossref","DOI":"10.21037\/tcr.2018.06.16","article-title":"Exposing cancer with CRISPR-Cas9: from genetic identification to clinical therapy","volume":"7","author":"Fan","year":"2018","journal-title":"Transl. Cancer Res."},{"issue":"9-10","key":"10.1016\/j.jbiotec.2026.06.012_bib25","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1089\/hum.2023.059","article-title":"Advances in CRISPR\/Cas9 genome editing for the treatment of muscular dystrophies","volume":"34","author":"Fatehi","year":"2023","journal-title":"Human. Gene Ther."},{"issue":"10","key":"10.1016\/j.jbiotec.2026.06.012_bib26","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/cr.2013.114","article-title":"Efficient genome editing in plants using a CRISPR\/Cas system","volume":"23","author":"Feng","year":"2013","journal-title":"Cell. Res."},{"issue":"7","key":"10.1016\/j.jbiotec.2026.06.012_bib27","doi-asserted-by":"crossref","first-page":"7079","DOI":"10.1007\/s11033-022-07442-w","article-title":"CRISPR\/Cas9 a simple, inexpensive and effective technique for gene editing","volume":"49","author":"Ferreira","year":"2022","journal-title":"Mol. Biol. Rep."},{"issue":"3","key":"10.1016\/j.jbiotec.2026.06.012_bib28","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.jbiotec.2026.06.012_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2024.07.015","article-title":"Safety and efficacy studies of CRISPR-Cas9 treatment of sickle cell disease highlights disease-specific responses","author":"Frati","year":"2024","journal-title":"Mol. Ther."},{"issue":"9","key":"10.1016\/j.jbiotec.2026.06.012_bib30","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.1002\/cam4.2257","article-title":"Therapeutic potential of CRISPR\/Cas9 gene editing in engineered T-cell therapy","volume":"8","author":"Gao","year":"2019","journal-title":"Cancer Med."},{"issue":"11","key":"10.1016\/j.jbiotec.2026.06.012_bib31","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.7150\/thno.42325","article-title":"Selective targeting of the oncogenic KRAS G12S mutant allele by CRISPR\/Cas9 induces efficient tumor regression","volume":"10","author":"Gao","year":"2020","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.jbiotec.2026.06.012_bib32","article-title":"Cellular reprogramming, genome editing, and alternative CRISPR Cas9 technologies for precise gene therapy of Duchenne muscular dystrophy","volume":"2017","author":"Gee","year":"2017","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.jbiotec.2026.06.012_bib33","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1590\/s1679-45082017rb4024","article-title":"Gene therapy: advances, challenges and perspectives","volume":"15","author":"Gon\u00e7alves","year":"2017","journal-title":"Einst (Sao Paulo)"},{"issue":"2","key":"10.1016\/j.jbiotec.2026.06.012_bib34","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.celrep.2017.12.041","article-title":"DNA unwinding is the primary determinant of CRISPR-Cas9 activity","volume":"22","author":"Gong","year":"2018","journal-title":"Cell. Rep."},{"issue":"8","key":"10.1016\/j.jbiotec.2026.06.012_bib35","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1134\/S0006297922080090","article-title":"CRISPR\u2013cas9: A history of its discovery and ethical considerations of its use in genome editing","volume":"87","author":"Gostimskaya","year":"2022","journal-title":"Biochemistry (Moscow)"},{"key":"10.1016\/j.jbiotec.2026.06.012_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1143157","article-title":"Off-target effects in CRISPR\/Cas9 gene editing","volume":"11","author":"Guo","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"1","key":"10.1016\/j.jbiotec.2026.06.012_bib37","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13020-022-00584-w","article-title":"CRISPR-Cas gene editing technology and its application prospect in medicinal plants","volume":"17","author":"Guo","year":"2022","journal-title":"Chin. Med."},{"issue":"6","key":"10.1016\/j.jbiotec.2026.06.012_bib38","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","article-title":"Development and applications of CRISPR-Cas9 for genome engineering","volume":"157","author":"Hsu","year":"2014","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.jbiotec.2026.06.012_bib39","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41433-022-02169-1","article-title":"The application and progression of CRISPR\/Cas9 technology in ophthalmological diseases","volume":"37","author":"Hu","year":"2023","journal-title":"Eye"},{"issue":"4","key":"10.1016\/j.jbiotec.2026.06.012_bib40","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1093\/plphys\/kiab591","article-title":"Improvement of base editors and prime editors advances precision genome engineering in plants","volume":"188","author":"Hua","year":"2022","journal-title":"Plant. Physiol."},{"issue":"1","key":"10.1016\/j.jbiotec.2026.06.012_bib41","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s11033-023-09086-w","article-title":"CRISPR-Cas9 based molecular breeding in crop plants: a review","volume":"51","author":"Ikram","year":"2024","journal-title":"Mol. Biol. Rep."},{"issue":"7","key":"10.1016\/j.jbiotec.2026.06.012_bib42","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1111\/jcmm.14916","article-title":"CRISPR\/Cas9-mediated genome editing: From basic research to translational medicine","volume":"24","author":"Jacinto","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.jbiotec.2026.06.012_bib43","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ymben.2015.12.003","article-title":"CRISPR\/Cas9 advances engineering of microbial cell factories","volume":"34","author":"Jako\u010di\u016bnas","year":"2016","journal-title":"Metab. Eng."},{"issue":"1","key":"10.1016\/j.jbiotec.2026.06.012_bib44","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/cge.13589","article-title":"Application of CRISPR\/Cas9 gene editing technique in the study of cancer treatment","volume":"97","author":"Jiang","year":"2020","journal-title":"Clin. Genet."},{"issue":"1","key":"10.1016\/j.jbiotec.2026.06.012_bib45","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","article-title":"CRISPR\u2013Cas9 structures and mechanisms","volume":"46","author":"Jiang","year":"2017","journal-title":"Annu. Rev. Biophys."},{"issue":"6096","key":"10.1016\/j.jbiotec.2026.06.012_bib46","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA\u2013guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"science"},{"issue":"11","key":"10.1016\/j.jbiotec.2026.06.012_bib47","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s13238-017-0477-4","article-title":"Addressing challenges in the clinical applications associated with CRISPR\/Cas9 technology and ethical questions to prevent its misuse","volume":"8","author":"Kang","year":"2017","journal-title":"Protein & Cell."},{"issue":"17","key":"10.1016\/j.jbiotec.2026.06.012_bib48","doi-asserted-by":"crossref","first-page":"6240","DOI":"10.3390\/ijms21176240","article-title":"CRISPR-Cas9 DNA base-editing and prime-editing","volume":"21","author":"Kantor","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.jbiotec.2026.06.012_bib49","doi-asserted-by":"crossref","first-page":"12267","DOI":"10.1002\/jcp.27972","article-title":"CRISPR\/Cas9 technology as a potent molecular tool for gene therapy","volume":"234","author":"Karimian","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"5","key":"10.1016\/j.jbiotec.2026.06.012_bib50","doi-asserted-by":"crossref","first-page":"5751","DOI":"10.1002\/jcp.27476","article-title":"CRISPR\u2013Cas9 in genome editing: Its function and medical applications","volume":"234","author":"Khadempar","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"5","key":"10.1016\/j.jbiotec.2026.06.012_bib51","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkac1254","article-title":"Detection of unintended on-target effects in CRISPR genome editing by DNA donors carrying diagnostic substitutions","volume":"51","author":"Lackner","year":"2023","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.jbiotec.2026.06.012_bib52","doi-asserted-by":"crossref","first-page":"11879","DOI":"10.1038\/s41598-018-30205-2","article-title":"Selective targeting of KRAS oncogenic alleles by CRISPR\/Cas9 inhibits proliferation of cancer cells","volume":"8","author":"Lee","year":"2018","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.jbiotec.2026.06.012_bib53","doi-asserted-by":"crossref","first-page":"354","DOI":"10.33594\/000000224","article-title":"CRISPR\/Cas9 technology in translational biomedicine","volume":"54","author":"Leonova","year":"2020","journal-title":"Cell. Physiol. Biochem."},{"issue":"3","key":"10.1016\/j.jbiotec.2026.06.012_bib54","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/bfgp\/elz042","article-title":"Applications and explorations of CRISPR\/Cas9 in CAR T-cell therapy","volume":"19","author":"Li","year":"2020","journal-title":"Brief. Funct. Genom."},{"issue":"1","key":"10.1016\/j.jbiotec.2026.06.012_bib55","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41392-023-01309-7","article-title":"CRISPR\/Cas9 therapeutics: progress and prospects","volume":"8","author":"Li","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.jbiotec.2026.06.012_bib56","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/jpm8040038","article-title":"Applications of CRISPR\/Cas9 for the treatment of Duchenne muscular dystrophy","volume":"8","author":"Lim","year":"2018","journal-title":"J. Pers. Med."},{"issue":"1","key":"10.1016\/j.jbiotec.2026.06.012_bib57","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12943-023-01738-6","article-title":"Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy","volume":"22","author":"Liu","year":"2023","journal-title":"Mol. Cancer"},{"issue":"15","key":"10.1016\/j.jbiotec.2026.06.012_bib58","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1007\/s00216-024-05301-0","article-title":"A Dual-mode platform for the rapid detection of Escherichia coli O157:H7 based on CRISPR\/Cas12a and RPA","volume":"416","author":"Luo","year":"2024","journal-title":"Anal. Bioanal. Chem."},{"issue":"9","key":"10.1016\/j.jbiotec.2026.06.012_bib59","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1080\/17425247.2018.1517746","article-title":"Delivery approaches for CRISPR\/Cas9 therapeutics in vivo: advances and challenges","volume":"15","author":"Luther","year":"2018","journal-title":"Expert. Opin. Drug. Deliv."},{"issue":"6","key":"10.1016\/j.jbiotec.2026.06.012_bib60","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/s12276-025-01465-6","article-title":"Extracellular vesicles derived from lung M2 macrophages enhance group 2 innate lymphoid cells function in allergic airway inflammation","volume":"57","author":"Lv","year":"2025","journal-title":"Exp. & Mol. Med."},{"key":"10.1016\/j.jbiotec.2026.06.012_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2023.147480","article-title":"CRISPR\/Cas9-based gene-editing technology for sickle cell disease","volume":"874","author":"Ma","year":"2023","journal-title":"Gene"},{"key":"10.1016\/j.jbiotec.2026.06.012_bib62","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/bs.pmbts.2021.01.017","article-title":"CRISPR-Cas9 for treating hereditary diseases","volume":"181","author":"Mani","year":"2021","journal-title":"Progress. Mol. Biol. Transl. Sci."},{"issue":"1","key":"10.1016\/j.jbiotec.2026.06.012_bib63","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1038\/s41467-020-18875-x","article-title":"vivo CRISPR\/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells","volume":"11","author":"Martinez-Lage","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbiotec.2026.06.012_bib64","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.omtn.2022.01.003","article-title":"Cardiac protection induced by urocortin-2 enables the regulation of apoptosis and fibrosis after ischemia and reperfusion involving miR-29a modulation","volume":"27","author":"Mayoral-Gonz\u00e1lez","year":"2022","journal-title":"Mol. Ther. -Nucleic Acids"},{"issue":"3","key":"10.1016\/j.jbiotec.2026.06.012_bib65","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s13311-022-01197-9","article-title":"CRISPR-Cas9 gene therapy for Duchenne muscular dystrophy","volume":"19","author":"Mbakam","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jbiotec.2026.06.012_bib66","first-page":"487","article-title":"CRISPR\/Cas9 gene-editing: Research technologies, clinical applications and ethical considerations","volume":"42","author":"Memi","year":"2018"},{"issue":"2","key":"10.1016\/j.jbiotec.2026.06.012_bib67","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current clinical applications of in vivo gene therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jbiotec.2026.06.012_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1148412","article-title":"Application of CRISPR-Cas9 gene editing technology in basic research, diagnosis and treatment of colon cancer","volume":"14","author":"Meng","year":"2023","journal-title":"Front. Endocrinol."},{"issue":"12","key":"10.1016\/j.jbiotec.2026.06.012_bib69","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.humimm.2018.09.007","article-title":"CRISPR\/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment","volume":"79","author":"Mollanoori","year":"2018","journal-title":"Human. Immunol."},{"issue":"2","key":"10.1016\/j.jbiotec.2026.06.012_bib70","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.gendis.2019.12.007","article-title":"Promising therapeutic approaches using CRISPR\/Cas9 genome editing technology in the treatment of Duchenne muscular dystrophy","volume":"8","author":"Mollanoori","year":"2021","journal-title":"Genes. & Dis."},{"issue":"1","key":"10.1016\/j.jbiotec.2026.06.012_bib71","first-page":"1","article-title":"Advances in the CRISPR\/Cas9 Mediated Genome Editing: A Review: CRISPR\/Cas9 Mediated Genome Editing","volume":"56","author":"Nawaz","year":"2019","journal-title":"Proc. Pak. Acad. Sci. B. Life Environ. Sci."},{"issue":"19","key":"10.1016\/j.jbiotec.2026.06.012_bib72","doi-asserted-by":"crossref","first-page":"5506","DOI":"10.1158\/0008-5472.CAN-18-0571","article-title":"Specific targeting of oncogenes using CRISPR technology","volume":"78","author":"Oppel","year":"2018","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.jbiotec.2026.06.012_bib73","first-page":"687","article-title":"Applications and developments of gene therapy drug delivery systems for genetic diseases","volume":"16","author":"Pan","year":"2021","journal-title":"Asian J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.jbiotec.2026.06.012_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2021.103060","article-title":"CRISPR\/Cas9 gene editing for curing sickle cell disease","volume":"60","author":"Park","year":"2021","journal-title":"Transfus. Apher. Sci."},{"issue":"17-18","key":"10.1016\/j.jbiotec.2026.06.012_bib75","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1089\/hum.2020.153","article-title":"Will airway gene therapy for cystic fibrosis improve lung function? New imaging technologies can help us find out","volume":"31","author":"Parsons","year":"2020","journal-title":"Human. Gene Ther."},{"issue":"7","key":"10.1016\/j.jbiotec.2026.06.012_bib76","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1111\/febs.13586","article-title":"Potential pitfalls of CRISPR\/Cas9-mediated genome editing","volume":"283","author":"Peng","year":"2016","journal-title":"FEBS J."},{"issue":"5","key":"10.1016\/j.jbiotec.2026.06.012_bib77","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3390\/cells10050969","article-title":"CRISPR-Cas and its wide-ranging applications: From human genome editing to environmental implications, technical limitations, hazards and bioethical issues","volume":"10","author":"Piergentili","year":"2021","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.jbiotec.2026.06.012_bib78","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3390\/cancers14040947","article-title":"Current status of CRISPR\/Cas9 application in clinical cancer research: opportunities and challenges","volume":"14","author":"Rafii","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.jbiotec.2026.06.012_bib79","first-page":"16","article-title":"Crispr-Cas9 Gene Editing: Ethical Considerations and Future Applications","author":"Ram","year":"2022","journal-title":"Int. J. Med. Phar. Drug. Re"},{"issue":"1","key":"10.1016\/j.jbiotec.2026.06.012_bib80","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ymthe.2021.08.019","article-title":"Combination of lentiviral and genome editing technologies for the treatment of sickle cell disease","volume":"30","author":"Ramadier","year":"2022","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.jbiotec.2026.06.012_bib81","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2174\/1566523223666221118160932","article-title":"Duchenne muscular dystrophy gene therapy","volume":"24","author":"Saad","year":"2024","journal-title":"Curr. Gene Ther."},{"issue":"10","key":"10.1016\/j.jbiotec.2026.06.012_bib82","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1002\/bit.27882","article-title":"Strengthening the CAR-T cell therapeutic application using CRISPR\/Cas9 technology","volume":"118","author":"Sadeqi Nezhad","year":"2021","journal-title":"Biotechnol. Bioeng."},{"issue":"3","key":"10.1016\/j.jbiotec.2026.06.012_bib83","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1124\/jpet.119.257287","article-title":"CRISPR\/Cas system for genome editing: progress and prospects as a therapeutic tool","volume":"370","author":"Sahel","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jbiotec.2026.06.012_bib84","article-title":"Erratic journey of CRISPR\/Cas9 in oncology from bench-work to successful-clinical therapy","volume":"27","author":"Sarkar","year":"2021","journal-title":"Cancer Treat. Res. Commun."},{"key":"10.1016\/j.jbiotec.2026.06.012_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120375","article-title":"Gene therapy: Comprehensive overview and therapeutic applications","volume":"294","author":"Sayed","year":"2022","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.jbiotec.2026.06.012_bib86","first-page":"108","article-title":"Advances in research on genome editing CRISPR-Cas9 technology","volume":"31","author":"Shah","year":"2018","journal-title":"J. Ayub Med. Coll. Abbottabad"},{"key":"10.1016\/j.jbiotec.2026.06.012_bib87","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3389\/fgene.2019.00868","article-title":"Development and clinical translation of approved gene therapy products for genetic disorders","volume":"10","author":"Shahryari","year":"2019","journal-title":"Front. Genet."},{"key":"10.1016\/j.jbiotec.2026.06.012_bib88","series-title":"Plant-Derived Anticancer Drugs in the OMICS Era","first-page":"251","article-title":"CRISPR\/Cas-Mediated Editing of Anticancer Plants","author":"Shan","year":"2023"},{"key":"10.1016\/j.jbiotec.2026.06.012_bib89","doi-asserted-by":"crossref","DOI":"10.1002\/iub.2896","article-title":"Utilizing adeno-associated virus as a vector in treating genetic disorders or human cancers","author":"Shih","year":"2024","journal-title":"IUBMB life"},{"issue":"1","key":"10.1016\/j.jbiotec.2026.06.012_bib90","doi-asserted-by":"crossref","first-page":"103","DOI":"10.21775\/cimb.026.103","article-title":"Ethical issues regarding CRISPR mediated genome editing","volume":"26","author":"Shinwari","year":"2018","journal-title":"Curr. Issues Mol. Biol."},{"issue":"1","key":"10.1016\/j.jbiotec.2026.06.012_bib91","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s11658-022-00336-6","article-title":"CRISPR\/Cas9 application in cancer therapy: a pioneering genome editing tool","volume":"27","author":"Shojaei Baghini","year":"2022","journal-title":"Cell. & Mol. Biol. Lett."},{"issue":"3","key":"10.1016\/j.jbiotec.2026.06.012_bib92","first-page":"1","article-title":"Gene Editing Technologies: CRISPR\/Cas9 and Beyond for Genetic Disease Therapy and Research","volume":"11","author":"Singh","year":"2024","journal-title":"Univers. Res. Rep."},{"issue":"7631","key":"10.1016\/j.jbiotec.2026.06.012_bib93","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nature20565","article-title":"vivo genome editing via CRISPR\/Cas9 mediated homology-independent targeted integration","volume":"540","author":"Suzuki","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jbiotec.2026.06.012_bib94","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1354825","article-title":"Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR\/Cas9 gene editing technology","volume":"15","author":"Tao","year":"2024","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.jbiotec.2026.06.012_bib95","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/biotech10030014","article-title":"Applications of CRISPR-Cas9 as an advanced genome editing system in life sciences","volume":"10","author":"Tavakoli","year":"2021","journal-title":"BioTech"},{"issue":"1","key":"10.1016\/j.jbiotec.2026.06.012_bib96","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41698-019-0080-7","article-title":"CRISPR\/Cas9\u2013An evolving biological tool kit for cancer biology and oncology","volume":"3","author":"Tian","year":"2019","journal-title":"NPJ Precis. Oncol."},{"issue":"3","key":"10.1016\/j.jbiotec.2026.06.012_bib97","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/bfgp\/elz039","article-title":"CRISPR\/Cas9 technology: towards a new generation of improved CAR-T cells for anticancer therapies","volume":"19","author":"Ure\u00f1a-Bail\u00e9n","year":"2020","journal-title":"Brief. Funct. Genom."},{"issue":"1","key":"10.1016\/j.jbiotec.2026.06.012_bib98","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s11658-022-00348-2","article-title":"CRISPR\/Cas9 gene editing: a new approach for overcoming drug resistance in cancer","volume":"27","author":"Vaghari-Tabari","year":"2022","journal-title":"Cell. & Mol. Biol. Lett."},{"issue":"7","key":"10.1016\/j.jbiotec.2026.06.012_bib99","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1080\/03639045.2017.1298122","article-title":"Gene delivery to the lungs: pulmonary gene therapy for cystic fibrosis","volume":"43","author":"Villate-Beitia","year":"2017","journal-title":"Drug. Dev. Ind. Pharm."},{"key":"10.1016\/j.jbiotec.2026.06.012_bib100","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.addr.2020.05.002","article-title":"Delivery of genome-editing biomacromolecules for treatment of lung genetic disorders","volume":"168","author":"Wan","year":"2021","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.jbiotec.2026.06.012_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114347","article-title":"A biocompatible tea polyphenol nanoplatform for efficient cytosolic delivery of protein therapeutics","volume":"388","author":"Wang","year":"2025","journal-title":"J. Control. Release"},{"issue":"11","key":"10.1016\/j.jbiotec.2026.06.012_bib102","doi-asserted-by":"crossref","first-page":"6001","DOI":"10.1016\/j.apsb.2025.08.003","article-title":"Arsenic trioxide-based nanoparticles for enhanced chemotherapy by activating pyroptosis","volume":"15","author":"Wang","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.jbiotec.2026.06.012_bib103","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-022-01518-8","article-title":"Current applications and future perspective of CRISPR\/Cas9 gene editing in cancer","volume":"21","author":"Wang","year":"2022","journal-title":"Mol. Cancer"},{"issue":"15","key":"10.1016\/j.jbiotec.2026.06.012_bib104","doi-asserted-by":"crossref","first-page":"12317","DOI":"10.3390\/ijms241512317","article-title":"CRISPR\/Cas9: A powerful strategy to improve CAR-T cell persistence","volume":"24","author":"Wei","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jbiotec.2026.06.012_bib105","article-title":"Synthesis of sustainable chromium-based nanoparticles with fluorescence tunable ability for biosensing of tumor-derived exosomes and molecular information protection","author":"Wu","year":"2025","journal-title":"SusMat"},{"issue":"10","key":"10.1016\/j.jbiotec.2026.06.012_bib106","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.7150\/thno.43360","article-title":"Advances in CRISPR\/Cas-based gene therapy in human genetic diseases","volume":"10","author":"Wu","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.jbiotec.2026.06.012_bib107","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1016\/j.csbj.2020.08.031","article-title":"CRISPR-Cas systems: Overview, innovations and applications in human disease research and gene therapy","volume":"18","author":"Xu","year":"2020","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"R1","key":"10.1016\/j.jbiotec.2026.06.012_bib108","doi-asserted-by":"crossref","first-page":"R88","DOI":"10.1093\/hmg\/ddz139","article-title":"Advances in gene therapy for cystic fibrosis lung disease","volume":"28","author":"Yan","year":"2019","journal-title":"Human. Mol. Genet."},{"key":"10.1016\/j.jbiotec.2026.06.012_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113664","article-title":"Transdermal psoriasis treatment inspired by tumor microenvironment-mediated immunomodulation and advanced by exosomal engineering","volume":"382","author":"Yang","year":"2025","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jbiotec.2026.06.012_bib110","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1631\/jzus.B2000282","article-title":"Target binding and residence: a new determinant of DNA double-strand break repair pathway choice in CRISPR\/Cas9 genome editing","volume":"22","author":"Yili","year":"2021","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"10.1016\/j.jbiotec.2026.06.012_bib111","first-page":"106","article-title":"CRISPR\/Cas9 for cancer research and therapy","volume":"55","author":"Zhan","year":"2019"},{"issue":"R2","key":"10.1016\/j.jbiotec.2026.06.012_bib112","doi-asserted-by":"crossref","first-page":"R79","DOI":"10.1093\/hmg\/ddy120","article-title":"Development and application of CRISPR\/Cas9 technologies in genomic editing","volume":"27","author":"Zhang","year":"2018","journal-title":"Human. Mol. Genet."},{"key":"10.1016\/j.jbiotec.2026.06.012_bib113","doi-asserted-by":"crossref","DOI":"10.1017\/S0033583519000052","article-title":"Development of CRISPR-Cas systems for genome editing and beyond","volume":"52","author":"Zhang","year":"2019","journal-title":"Q. Rev. Biophys."},{"key":"10.1016\/j.jbiotec.2026.06.012_bib114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-021-01431-6","article-title":"Application of the CRISPR\/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer","volume":"20","author":"Zhang","year":"2021","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.jbiotec.2026.06.012_bib115","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/cge.13717","article-title":"Applications of CRISPR-Cas9 in gynecological cancer research","volume":"97","author":"Zhang","year":"2020","journal-title":"Clin. Genet."},{"key":"10.1016\/j.jbiotec.2026.06.012_bib116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12575-021-00151-x","article-title":"Review of applications of CRISPR-Cas9 gene-editing technology in cancer research","volume":"23","author":"Zhao","year":"2021","journal-title":"Biol. Proced. Online"},{"issue":"6","key":"10.1016\/j.jbiotec.2026.06.012_bib117","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1159\/000486168","article-title":"Oncogenic human papillomavirus: application of CRISPR\/Cas9 therapeutic strategies for cervical cancer","volume":"44","author":"Zhen","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"issue":"1","key":"10.1016\/j.jbiotec.2026.06.012_bib118","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s43556-023-00115-5","article-title":"Recent advances in therapeutic CRISPR-Cas9 genome editing: mechanisms and applications","volume":"4","author":"Zhou","year":"2023","journal-title":"Mol. Biomed."}],"container-title":["Journal of Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168165626001896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168165626001896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:58:25Z","timestamp":1783443505000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168165626001896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":118,"alternative-id":["S0168165626001896"],"URL":"https:\/\/doi.org\/10.1016\/j.jbiotec.2026.06.012","relation":{},"ISSN":["0168-1656"],"issn-type":[{"value":"0168-1656","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CRISPR Cas9 revolutionizing genetic engineering and therapeutic applications","name":"articletitle","label":"Article Title"},{"value":"Journal of Biotechnology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbiotec.2026.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}